Clinical Trial

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\[68Ga\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-14; most recent amendment 2025-05-29.
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06419361
Lead Sponsor First Affiliated Hospital of Chongqing Medical University
Conditions Stimulator of Interferon Gene, Cancer, Positron Emission Tomography
Enrollment 30 participants
Start Date 2024-05-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-04